In May of 2023, we hosted a 60-minute fireside chat with Paul Petraro on best practices for holistic Real-World Evidence. Paul works as an Executive Director and Global Heads in RWE at the Analytic Evidence Center at Boehringer Ingelheim, where he ensures the management and oversight of real-world studies along with developing RWE strategies. As a trained epidemiologist with a strong background in epidemiology methods and evidence, he is experienced in observational and experimental studies, fast authorization and risk management. Paul also has an in-depth knowledge of public and private epide ..read more

Introduction Given their position as influential thought leaders in their field, Key Opinion Leaders (KOLs) are highly sought after by pharma companies in the healthcare industry. This position leads to a tightly packed work schedule and means that KOLs have very little time on their hands. As a result, Medical Science Liaison managers (MSLs) – who are trusted scientific advisors to HCPs and must convey truthful medical and scientific information to them – can struggle when trying to reach them and present new medical data from their company. This blog post will showcase how MSLs can succ ..read more

The use of mobile devices, wearables, computers and similar products which collect and store large amounts of health-related data has grown rapidly over the past few years. As a result, so-called Real-World Data (RWD) and its potential have become a growing focal point for many stakeholders in healthcare. In a previous article, we discussed the current challenges of Real-World Data and were able to show practical approaches to solving them. This time, we will look at the advantages of Real-World Data: What benefits does it offer for research and how can the healthcare system as a whole benefit ..read more

Introduction: In the fall of 2023, we collaborated with Siteworks Clinical Research to conduct a survey aiming to understand trial physicians’ perspectives on clinical trials and capture the current state of clinical research. This is increasingly important as investigator recruitment and retention significantly impact clinical trial sponsors. We surveyed 66 study physicians from various therapeutic specialties, with most based in Europe. The questionnaire included 19 questions covering different topics, such as: 1. Status Quo: Gathering essential data on past study involvement and the factors ..read more

Introduction Although clinical trials are aimed at studying treatments for the population as a whole, their findings are often based on data from the small percentage of patients that actually participate. This is typically a very homogeneous group: Most participants tend to be white males.  Unfortunately, this means that women, children, elderly people or those of other ethnic origins or socioeconomic backgrounds suffering from the same disease are not adequately represented.  But representation matters because different subgroups may experience the same disease very differently. Po ..read more

Introduction Given their position as influential thought leaders in their field, Key Opinion Leaders (KOLs) are highly sought after by pharma companies in the healthcare industry. This position leads to a tightly packed work schedule and means that KOLs have very little time on their hands. As a result, Medical Science Liaison managers (MSLs) – who are trusted scientific advisors to HCPs and must convey truthful medical and scientific information to them – can struggle when trying to reach them and present new medical data from their company. This blog post will showcase how MSLs can succ ..read more

As we approach the end of 2023, it’s time to revisit the best of our content-related moments that were part of Climedo’s journey. Throughout this year, our commitment to knowledge-sharing took shape through a series of Climedo Connect webinars and content. We had the privilege of hosting insightful sessions with great speakers, each contributing their views and expertise to the evolving landscape of healthcare and technology. Early in the year, our patient survey uncovered a patient perspective on clinical trials, enriching our understanding of what’s going well and what needs to change in the ..read more

Introduction A Phase IV clinical trial, also known as a post-marketing surveillance trial or a post-approval study, is conducted after a new treatment (such as a pharmaceutical product or medical device) has been approved by regulatory agencies and has entered the market. It represents a pivotal phase in a product’s journey from development to market availability. Unlike earlier phases of clinical trials, which primarily focus on evaluating the treatment’s quality, safety and efficacy, Phase IV clinical trials are designed to gather additional information about the product’s real-world use, lo ..read more

This year, we developed two exciting software features – eConsent and Self-Registration – which enable a smooth study experience for patients and assist with patient recruitment in a hybrid environment. Find out how the features came about and exactly how it all works in this post. What’s it about?  1) Digital patient recruitment and lower entry barriers 2) Self-Registration  3) eConsent 4) The shift towards fully virtual trials   1) Digital patient recruitment and lower entry barriers  A recent survey by Climedo and Trials24 among over 120 participants revealed that t ..read more

In an ever-evolving healthcare landscape, embracing patient-centric approaches in clinical trials is crucial. That’s why, in early 2023 we organized a thought-provoking CRO workshop titled “The Future of Patient Centricity in Clinical Trials.” The event aimed to foster innovative discussions around the present and future of clinical research, and to establish new connections within our CRO network. What was the CRO workshop about  – Quick overview: 1) Part 1: Futures thinking 1a) Clinical trials in the metaverse 1b) Personalized medicine through AI and wearable devices 2) Part 2: Data ins ..read more